MREO Stock Forecast & Price Target

Mereo BioPharma Group is attractive because it has multiple late-stage rare-disease assets with differentiated commercial paths, led by alvelestat in AATD-LD and setrusumab in osteogenesis imperfecta, both addressing high unmet need populations. The Sentynl option agreement externally validates alvelestat and could deliver a non-refundable option fee, $40M in upfront and R&D payments, up to $435M in milestones, and double-digit U.S. royalties, while Mereo retains ex-U.S. rights and keeps leading Phase 3 development. Fundamentally, the company also has a manageable cash position of $30.1M at 2Q26, guided to fund operations into late 2027, and setrusumab’s data showed meaningful bone mineral density improvement with a favorable safety profile despite mixed fracture endpoints.

Mereo BioPharma Group is facing a fundamentally weak investment case because setrusumab failed to hit the core efficacy goals in the Phase 3 ORBIT trial, missing both the primary fracture-reduction endpoint and the key secondary fracture endpoint with p-values of 0.305 and 0.865, respectively. Although the drug improved bone mineral density and some pain-related measures, those benefits are secondary and do not offset the lack of demonstrated fracture protection in 159 patients, including a meaningful 19.5% who met rescue criteria by 12mo. The safety profile was generally clean, but in a rare-disease biotech, positive tolerability cannot compensate for a program that has not proved it can deliver the clinically meaningful outcome investors need.